Compare Crispr Therapeutics AG (CRSP) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Orion Office REIT Inc — how do they compare? Crispr Therapeutics AG trades at $53.26 (market cap $4.88B), while Orion Office REIT Inc trades at $2.18 (market cap $125.50M). The key difference: Crispr Therapeutics AG is far larger — about 38.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Orion Office REIT Inc for 33 Days on average.
| CRSP | ONL | |
|---|---|---|
Market Cap | $4.88B | $125.50M |
Volume | 2,861,747 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $74.92 | $3.00 |
52-Week Low | $44.34 | $1.93 |
Typical Hold Time | 77 Days | 33 Days |
Enterprise Value | $3.30B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
ONL trades at $2.19, down 3.52% today, with a bearish technical signal despite a recent earnings beat. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Positive cash flow of $3.47M in 2025 and a low P/B of 0.2 offer value, but high debt and negative margins pose challenges. Analysts are split 50/50 between Buy and Hold.
Outlook remains cautious; deep discount to book value and strategic portfolio repositioning may attract value investors, but sustained losses and office sector headwinds limit near-term upside. Key risks include leverage pressure and execution of turnaround plans amid weak demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
